NeuroSense Announces Pricing of Insider-Led PIPE Financing

Rhea-AI Summary

NeuroSense (NASDAQ: NRSN) announced a definitive agreement for a $600,000 insider-led private placement of 750,000 ordinary shares at $0.80 per share, a price 6.7% above the April 27, 2026 close. The offering includes $200,000 commitments each from CEO Alon Ben-Noon, CFO Or Eisenberg, and a significant existing shareholder. The private placement is expected to close during the week of May 3, 2026, is subject to customary closing conditions, and proceeds will be used for general corporate purposes ahead of upcoming clinical and regulatory milestones.

Positive

• Insider participation: CEO and CFO each committed $200,000
• Existing investor also committed $200,000
• Price set at $0.80 per share, a 6.7% premium to Apr 27 close
• Proceeds to fund near-term clinical and regulatory milestones

Negative

• Small raise: total proceeds are only $600,000
• Share issuance of 750,000 ordinary shares may dilute existing holders
• Offering subject to closing conditions, not guaranteed to close during week of May 3, 2026

News Market Reaction – NRSN

+7.78% 2.1x vol

6 alerts

+7.78% Session close to close

+6.2% Peak in 5 hr 6 min

$30.40M Market Cap

2.1x Rel. Volume

In the Apr 28 session, NRSN gained 7.78%, reflecting a notable positive market reaction. Argus tracked a peak move of +6.2% during that session. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility. Trading volume was elevated at 2.1x the daily average, suggesting notable buying interest.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved +7.8% in the session following this news. A strong positive reaction aligns with an ...

Analysis

The stock moved +7.8% in the session following this news. A strong positive reaction aligns with an insider-led PIPE priced at $0.80, a 6.7% premium to the prior close, signaling confidence from the CEO, CFO, and a significant shareholder. Against prior disclosures of only $0.2M in cash and a $11.125M 2025 net loss, this $600,000 raise and the existing $150,000,000 Form F-3 shelf highlight both improved near-term funding visibility and ongoing financing dependence.

Key Figures

PIPE gross proceeds: $600,000 PIPE share price: $0.80 per share Shares in PIPE: 750,000 ordinary shares +5 more

8 metrics

PIPE gross proceeds $600,000 Insider-led private placement announced April 28, 2026

PIPE share price $0.80 per share Private placement pricing, 6.7% above April 27, 2026 close

Shares in PIPE 750,000 ordinary shares Aggregate shares to be sold in the private placement

Insider commitments $200,000 each CEO, CFO, and a significant existing investor in the PIPE

Year-end cash $0.2M Cash balance at December 31, 2025 from prior earnings release

2025 net loss $11.125M Full-year 2025 net loss from prior earnings release

Shelf registration size $150,000,000 Form F-3 shelf filed January 29, 2026

ATM program size $6,525,000 Capital on Demand at-the-market program under Form F-3

Historical Context

5 past events · Latest: Apr 06 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 06	Patent grant	Positive	-8.2%	Brazilian patent grant for PrimeC extending IP protection to October 2042.
Mar 31	Earnings update	Neutral	+3.3%	Year-end 2025 results with strong PrimeC data but low cash and net loss.
Mar 24	Regulatory update	Positive	-1.5%	Regulatory and clinical progress update for PrimeC with upcoming readouts.
Mar 18	Conference data	Positive	-5.4%	AD/PD 2026 presentation of new Phase 2b PARADIGM data for PrimeC.
Mar 18	Press correction	Neutral	-5.4%	Correction release reiterating PARADIGM and PARAGON details for PrimeC.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent positive clinical and IP updates have often coincided with negative price reactions, suggesting a tendency for the stock to sell off or fade on good news.

Recent Company History

Over the last few months, NeuroSense has highlighted strengthening fundamentals around PrimeC, including Brazilian patent protection through October 2042, multiple global patents, and advancement toward a pivotal Phase 3 PARAGON ALS trial. Financially, 2025 results showed just $0.2M in cash and a $11.125M net loss, underscoring reliance on external funding. Several clinical and regulatory milestones in March–April 2026 produced mixed-to-negative price reactions, providing context for today’s insider-led PIPE financing.

Key Terms

pipe financing, private placement, section 4(a)(2), regulation d, +4 more

8 terms

pipe financing financial

"NeuroSense Announces Pricing of Insider-Led PIPE Financing"

Pipe financing is a way for companies to raise money quickly by selling new shares or bonds directly to investors, often before their stock is publicly traded or in the early stages of a project. It’s similar to a company securing a loan from investors, providing quick capital needed for growth or operations. For investors, it can offer opportunities for early involvement and potentially higher returns, but it may also carry increased risk due to the immediate nature of the deal.

private placement financial

"announced the entry into a definitive agreement with certain investors to purchase $600,000 of ordinary shares in a private placement."

A private placement is a sale of securities directly to a selected group of investors, typically institutions or accredited investors, instead of through a public offering. It lets a company raise money faster and with fewer regulatory steps; for existing shareholders it matters because the newly issued shares, often sold at a discount, increase the share count and can dilute their ownership.

section 4(a)(2) regulatory

"being made in reliance on an exemption from registration under Section 4(a)(2) of the Securities Act"

Section 4(a)(2) is a part of U.S. securities laws that allows companies to sell their stock directly to certain investors without registering the sale with regulators. This process is often used for private placements, making it easier and faster for companies to raise money from knowledgeable or institutional investors. It matters to investors because it provides an alternative way to buy shares, often with fewer disclosures and lower costs.

regulation d regulatory

"Section 4(a)(2) of the Securities Act and/or Regulation D thereunder."

Regulation D is a set of rules that govern how companies can raise money from investors without going through the full process required for public stock offerings. It provides simplified options for private placements, making it easier for companies to seek investments from a smaller group of investors. For investors, it offers opportunities to invest in private companies, often with fewer restrictions, but also with different levels of risk and disclosure.

securities act regulatory

"except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act"

A securities act is a law that governs the offering, sale and disclosure of stocks, bonds and other investment products to the public. It requires companies to provide clear, truthful information—like a product label for an investment—so buyers can understand risks and value before they invest. For investors, these rules reduce fraud, promote transparency, and help ensure fair access to market information.

form f-3 regulatory

"has filed a Form F-3 shelf registration to offer up to $150,000,000 of securities"

Form F-3 is a U.S. securities filing that lets eligible foreign companies pre-register and then quickly sell shares or other securities to raise money, because they already meet ongoing reporting and size tests. For investors it signals that the company is up-to-date with regulatory disclosure and has an efficient way to issue new securities — similar to a pre-approved credit line — which can mean faster capital raises but also potential dilution of existing holdings.

shelf registration regulatory

"Form F-3 shelf registration to offer up to $150,000,000 of securities"

Shelf registration is when a company gets permission ahead of time to sell new stocks or bonds over a period of time instead of all at once. It matters to investors because it lets a company raise money quickly when needed, but it can also change the value of existing shares if many new ones are sold.

View in glossary

at-the-market program financial

"supports a Capital on Demand at-the-market program of up to $6,525,000 in ordinary shares"

An at-the-market program is a way for a company to sell new shares of its stock gradually over time directly into the stock market, rather than all at once. This approach allows the company to raise money as needed while giving investors the opportunity to buy shares at current market prices. It helps manage the timing and price of new stock offerings, providing flexibility for both the company and investors.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Financing led by CEO Alon Ben-Noon and CFO Or Eisenberg, alongside participation from an existing significant shareholder

CAMBRIDGE, Mass., April 28, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced the entry into a definitive agreement with certain investors to purchase $600,000 of ordinary shares in a private placement. In connection with the offering, NeuroSense agreed to sell an aggregate of 750,000 ordinary shares at a price of $0.80 per share, representing a purchase price of 6.7% above the closing pricing of NeuroSense's ordinary shares on April 27, 2026.

The private placement is subject to customary closing conditions and is expected to close during the week of May 3, 2026.

The private placement included participation from Company insiders and a leading existing shareholder. Chief Executive Officer Alon Ben-Noon, Chief Financial Officer Or Eisenberg, and a significant existing investor each committed $200,000 in the offering.

The Company intends to use the proceeds for general corporate purposes ahead of upcoming clinical and regulatory milestones.

The offering is being made in reliance on an exemption from registration under Section 4(a)(2) of the Securities Act and/or Regulation D thereunder. Accordingly, the securities issued in the offering may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About NeuroSense

NeuroSense Therapeutics, Ltd. is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. NeuroSense believes that these diseases, which include amyotrophic lateral sclerosis (ALS), Alzheimer's disease and Parkinson's disease, among others, represent one of the most significant unmet medical needs of our time, with limited effective therapeutic options available for patients to date. Due to the complexity of neurodegenerative diseases and based on strong scientific research on a large panel of related biomarkers, NeuroSense's strategy is to develop combined therapies targeting multiple pathways associated with these diseases.

For additional information, we invite you to visit our website and follow us on LinkedIn, YouTube and X. Information that may be important to investors may be routinely posted on our website and these social media channels.

Forward-Looking Statements

This press release contains "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will" "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on NeuroSense Therapeutics' current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict and include statements regarding the timing of regulatory filings, meetings and regulatory decisions. Further, certain forward-looking statements, including statements regarding the offering, including as to the consummation of the offering described above, the expected gross proceeds from the offering, the intended use of proceeds and the timing of the receipt of proceeds of the offering, are based on assumptions as to future events that may not prove to be accurate. The future events and trends may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward looking statements. These risks include the uncertainty regarding outcomes and the timing of current and future clinical trials; timing for reporting data, including from the study of PrimeC in Alzheimer's disease; that the study will not be successful; the ability of NeuroSense to remain listed on Nasdaq; and other risks and uncertainties set forth in NeuroSense's filings with the Securities and Exchange Commission (SEC). You should not rely on these statements as representing our views in the future. More information about the risks and uncertainties affecting NeuroSense is contained under the heading "Risk Factors" in the Annual Report on Form 20-F filed with the Securities and Exchange Commission on April 7, 2025 and NeuroSense's subsequent filings with the SEC. Forward-looking statements contained in this announcement are made as of this date, and NeuroSense undertakes no duty to update such information except as required under applicable law.

Logo: https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg

View original content:https://www.prnewswire.com/news-releases/neurosense-announces-pricing-of-insider-led-pipe-financing-302756142.html

SOURCE NeuroSense

FAQ

What are the terms of NeuroSense's (NRSN) insider-led PIPE financing announced April 28, 2026?

The financing is a private placement of 750,000 ordinary shares at $0.80 per share, totaling $600,000. According to the company, the price is 6.7% above the April 27, 2026 closing price.

Who participated in NeuroSense's (NRSN) April 2026 private placement and how much did insiders invest?

CEO Alon Ben-Noon and CFO Or Eisenberg each committed $200,000, with a significant existing shareholder also investing $200,000. According to the company, these three commitments make up the full $600,000 placement.

When is the NeuroSense (NRSN) private placement expected to close and what conditions apply?

The company expects the private placement to close during the week of May 3, 2026, subject to customary closing conditions. According to the company, the transaction is not final until those conditions are satisfied.

How will NeuroSense (NRSN) use the proceeds from the $600,000 offering announced April 28, 2026?

The company intends to use proceeds for general corporate purposes ahead of upcoming clinical and regulatory milestones. According to the company, funds are meant to support near-term operational and development activities.

Does NeuroSense's (NRSN) offering imply immediate registration of the new shares for public resale?

No. The securities were issued in reliance on exemptions from registration and may not be offered or sold in the U.S. absent an effective registration statement or applicable exemption. According to the company, resale is restricted by securities laws.

What shareholder impact should investors expect from NeuroSense's (NRSN) April 28, 2026 financing?

Investors should expect modest dilution from 750,000 new ordinary shares issued in the placement. According to the company, the raise is small in size but will increase share count and subject to customary closing risks.